Britain and America have reached a landmark trade agreement that will guarantee zero tariffs on UK drug exports being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to increase expenditure on medicines through the public health system. This commitment guarantees that import taxes on these crucial exports will remain at nothing for a timeframe of the next three years.
This deal comes after recent threats to significantly raise duties on patented drug imports, with increases mentioned as high as double the cost.
"This arrangement between the UK reinforces the global environment for cutting-edge drugs and establishes long-overdue equity to American-British pharmaceutical trade," a statement noted.
Trade Significance
Medicines constitute one of the the United Kingdom's largest goods shipped to the America, which is by far the biggest market for large British pharmaceutical firms.
Export figures indicate that in the one-year period to the end of September, the UK sold drugs totaling over eleven billion pounds to the US. This figure represented a significant portion of all goods exports in that period.
"This agreement secures employment, stimulates investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Key NHS Changes
The pact involves several specific changes from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to increase overall public funding on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to stay within budget will be capped at 15%. In the past, refunds exceeded 20%.
Broader Context
The deal takes place against a ongoing tension between the drug companies and the ministers over medicine costs and NHS adoption.
The disagreement were heightened by claims that US patients were charged a premium for the same drugs than patients in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been halted or cancelled, while major investments have been pledged toward US facilities.
A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
